Serum Level of Interleukin-10 in Patients with Head and neck Squamous Cell Carcinoma

Objective:The aim of this study was to examined serum IL-10 levels in patients with HNSCC to elucidate its association with clinicopathologic parameters. Study design:Using an ELISA kit, we assessed the circulating levels of IL-10 in sera from 60 head and neck squamous cell carcinoma (HNSCC) patients as well as from 30 healthy controls. Results: The serum IL10 concentration in HNSCC patients was significantly higher (14.08 ± 5.12 pg/ml, n=60) compared with healthy controls (4.4± 2.1 pg/ml, n=30; p<0.005). The serum levels of IL10 were greater in patients with III/IV-stage tumors than in patients with I/II stage tumors. (19.3± 1.1.2 pg/ml, n=29 vs 9.1±0.9 pg/ml, n=31, p<0.0005) and greater in T3/T4 tumor status than in T1/T2 tumor status (21.69± 2.41 pg/ml, n=19 vs 10.56±1.31 pg/ml, n=41, p<0.0005). The serum concentration of IL10 was greater in patients with nodal metastasis than in patients without nodal metastasis (19.1±1.6 pg/ml, n=29 vs 9.4± 1.4 pg/ml, n=31) Conclusions: Serum IL10 level is increased in HNSCC patients and this increase is an adverse prognostic factor.